Thermo Fisher Scientific Inc.
TMO
NYSE
467.68
USD-9.60(-2.01%)
As of today
Thermo Fisher Scientific Inc. fundamentals
Key ratios
Statements Highlights
Period Ending | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | |
---|---|---|---|---|---|---|
Total Revenue | 32,218,000,000 | 39,211,000,000 | 44,915,000,000 | 42,857,000,000 | 42,879,000,000 | |
Gross Profit | 16,505,000,000 | 20,234,000,000 | 19,500,000,000 | 17,113,000,000 | 17,702,000,000 | |
Operating Income | 7,794,000,000 | 10,028,000,000 | 8,393,000,000 | 6,859,000,000 | 7,337,000,000 | |
Net Income | 6,375,000,000 | 7,725,000,000 | 6,950,000,000 | 5,995,000,000 | 6,335,000,000 | |
Total Assets | 69,052,000,000 | 95,123,000,000 | 97,154,000,000 | 98,726,000,000 | 97,321,000,000 | |
Total Current Liabilities | 10,304,000,000 | 13,436,000,000 | 17,010,000,000 | 14,012,000,000 | 13,332,000,000 | |
Total Equity | 34,517,000,000 | 40,977,000,000 | 44,148,000,000 | 46,842,000,000 | 49,671,000,000 | |
Free Cash Flow | 6,815,000,000 | 7,020,000,000 | 6,911,000,000 | 6,927,000,000 | 7,267,000,000 | |
Cash from Operations | 8,289,000,000 | 9,543,000,000 | 9,154,000,000 | 8,406,000,000 | 8,667,000,000 | |
Cash from Investing | -1,510,000,000 | -21,932,000,000 | -2,159,000,000 | -5,142,000,000 | -5,841,000,000 | |
Cash from Financing | 959,000,000 | 6,581,000,000 | -2,810,000,000 | -3,622,000,000 | -6,792,000,000 | |
Net Change in Cash | 7,914,000,000 | -5,845,000,000 | 4,046,000,000 | -440,000,000 | -4,057,000,000 |